The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01).
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Maria Di Bartolomeo
Honoraria - Lilly; MSD Oncology; SERVIER
Consulting or Advisory Role - Lilly; MSD Oncology
Research Funding - Lilly
Travel, Accommodations, Expenses - Roche; Sanofi
 
Kanwal Pratap Singh Raghav
Consulting or Advisory Role - AstraZeneca; Bayer; Daiichi Sankyo; Eisai
Speakers' Bureau - Bayer
Research Funding - Bayer (Inst); Daiichi Sankyo/Lilly (Inst); Guardant Health (Inst); Roche/Genentech (Inst)
 
Toshiki Masuishi
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Hisato Kawakami
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo; Lilly Japan; Merck Serono; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo Co. Ltd.,; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst)
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Tomohiro Nishina
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Zev A. Wainberg
Consulting or Advisory Role - Amgen; Array BioPharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Five Prime Therapeutics; Ipsen; Lilly; Macrogenics; Merck; Merck KGaA; Novartis; QED Therapeutics
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Bayer; Lilly; Merck
 
Elena Elez
Honoraria - Abbvie/Genentech (Inst); Amgen (Inst); Array BioPharma; AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb; GlaxoSmithKline (Inst); Merck Serono; MSD (Inst); Novartis (Inst); Roche; Sanofi/Aventis; SERVIER
Consulting or Advisory Role - Amgen; Array BioPharma; Bayer; Bristol Myers Squibb; Merck Serono; Roche; Sanofi; SERVIER
Research Funding - Amgen; Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Merck Serono; Roche (Inst); Sanofi/Aventis (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck Serono; Roche; Sanofi; SERVIER
 
Javier Rodriguez
No Relationships to Disclose
 
Marwan Fakih
Honoraria - Amgen
Consulting or Advisory Role - Amgen; Array BioPharma; Bayer; GlaxoSmithKline; Incyte; Pfizer; Seagen; Taiho Pharmaceutical; Zhuhai DL Biotech
Speakers' Bureau - Guardant Health
Research Funding - Amgen (Inst); AstraZeneca (Inst); Novartis (Inst)
 
Fortunato Ciardiello
Consulting or Advisory Role - Amgen; Bayer; Merck KGaA; Pfizer; Roche/Genentech
Research Funding - Amgen (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Roche/Genentech (Inst); SERVIER (Inst); Symphogen (Inst)
 
Kapil Saxena
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Kojiro Kobayashi
Employment - Daiichi Sankyo
 
Emarjola Bako
Stock and Other Ownership Interests - Daiichi Sankyo
 
Yasuyuki Okuda
Employment - Daiichi Sankyo
 
Gerold Meinhardt
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Axel Grothey
Honoraria - Aptitude Health; Elsevier; IMEDEX
Consulting or Advisory Role - Amgen (Inst); Array BioPharma (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Genentech/Roche; Lilly (Inst); OBI Pharma
Research Funding - Array BioPharma (Inst); Bayer (Inst); Boston Biomedical (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Genentech/Roche
 
Salvatore Siena
Stock and Other Ownership Interests - Guardant Health; Myriad Genetics
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; CheckmAb; Clovis Oncology; Daiichi Sankyo; Incyte; Merck; Novartis; Roche/Genentech; Seagen
Research Funding - MSD Oncology (Inst)
Patents, Royalties, Other Intellectual Property - Amgen
Travel, Accommodations, Expenses - Amgen; Bayer; Roche